Upgrade to SI Premium - Free Trial

CytomX Therapeutics (CTMX)

2.95 -0.01 (0.34%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Form 4 CytomX Therapeutics, For: Jun 15 Filed by: Ogden Christopher June 17, 2026 6:39 PM - SEC Filing Form 8-K CytomX Therapeutics, For: May 29 June 3, 2026 4:15 PM - SEC Filing CytomX expands Regeneron collaboration, receives $37 million payment June 3, 2026 8:03 AM - StreetInsider CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer June 3, 2026 8:00 AM - Globe NewsWire CytomX Therapeutics to Present at Upcoming June Investor Conferences May 21, 2026 8:00 AM - Globe NewsWire Wolfe Research Starts CytomX Therapeutics (CTMX) at Outperform May 19, 2026 5:32 AM - StreetInsider CytomX hires Mamata Gokhale as regulatory affairs head May 18, 2026 8:01 AM - StreetInsider CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs May 18, 2026 8:00 AM - Globe NewsWire Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Seven Fleet Capital Management LP May 15, 2026 5:12 PM - SEC Filing Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Longitude Capital Partners V, LLC May 15, 2026 4:50 PM - SEC Filing Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P. May 15, 2026 4:43 PM - SEC Filing Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Kynam Capital Management, LP May 15, 2026 4:02 PM - SEC Filing Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC May 15, 2026 4:00 PM - SEC Filing CytomX Therapeutics (CTMX) PT Lowered to $11 at H.C. Wainwright May 11, 2026 6:59 AM - StreetInsider CytomX Therapeutics (CTMX) Tops Q1 EPS by 2c May 7, 2026 5:40 PM - StreetInsider CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update May 7, 2026 4:15 PM - Globe NewsWire Form 8-K CytomX Therapeutics, For: May 07 May 7, 2026 4:15 PM - SEC Filing Form 10-Q CytomX Therapeutics, For: Mar 31 May 7, 2026 4:07 PM - SEC Filing Form DEFA14A CytomX Therapeutics, April 30, 2026 4:26 PM - SEC Filing Form DEF 14A CytomX Therapeutics, For: Jun 17 April 30, 2026 4:21 PM - SEC Filing CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 April 30, 2026 8:00 AM - Globe NewsWire Form PRE 14A CytomX Therapeutics, For: Jun 17 April 20, 2026 4:16 PM - SEC Filing Increasing unusual put option volume: CTMX BEKE CAR VIAV BK BB MDLN TVTX EA BCS April 17, 2026 6:03 AM - StreetInsider Form SCHEDULE 13G CytomX Therapeutics, Filed by: Point72 Asset Management, L.P. April 16, 2026 4:10 PM - SEC Filing Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: VANGUARD GROUP INC March 26, 2026 5:40 PM - SEC Filing Jefferies on CytomX Therapeutics (CTMX): 'we see good entry point at current value' amid Vareseta-M derisking March 24, 2026 10:19 AM - StreetInsider CytomX Therapeutics (CTMX) PT Raised to $12 at Piper Sandler March 23, 2026 9:29 AM - StreetInsider Full Article List